Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it ...

Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide) quickly reached blockbuster status within their ...

Significant growth in demand for pharmaceuticals, such as GLP-1s, increased R&D spending for autonomous manufacturing, and ...

West Pharmaceutical's strong GLP-1 and biologics segment positions it for growth. Click here to read why WST stock is ...

(res), a leading physician-developed supplement brand, announced today the launch of their latest product innovation, resM™ GLP-1 Postbiotic. resM™ is a groundbreaking GLP-1 postbiotic supplement ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...

Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

The GLP-1 drug market has been dominated by pharmaceutical ... and U.S. Senator Roger Marshall, M.D. (R-KS) sent a bipartisan letter to the FDA flagging Hims & Hers' ad and accusing the company ...